New hope for kids with MS: Head-to-Head drug trial launches

NCT ID NCT06408259

Recruiting now Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two daily pills, ozanimod and fingolimod, to see which works better at preventing MS relapses in children and teens aged 10 to 17. Participants will be randomly assigned to one of the two drugs and monitored for about two years. The goal is to find a more effective and safer option for managing this chronic condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS, RELAPSING-REMITTING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

2Ca Braga
RECRUITING

Braga, 4710-243, Portugal
CHUVI- Hospital Alvaro Cunqueiro
RECRUITING

Vigo, Pontevedra [Pontevedra], 36203, Spain
Centro Hospitalar de Lisboa Central
RECRUITING

Lisbon, 1169-050, Portugal
Hospital Universitari i Politecnic La Fe
RECRUITING

Valencia, 46026, Spain
Hospital Universitario Miguel Servet
RECRUITING

Zaragoza, 50009, Spain
Hospital Universitario Virgen Macarena
RECRUITING

Seville, 41009, Spain
Local Institution - 0078
WITHDRAWN

Mexico City, DIF, 04530, Mexico
Local Institution - 0081
NOT_YET_RECRUITING

Milan, Lombardy, 20133, Italy
Local Institution - 0091
WITHDRAWN

Cincinnati, Ohio, 45229, United States
Local Institution - 0092
NOT_YET_RECRUITING

Portland, Oregon, 97225, United States
Local Institution - 0093
WITHDRAWN

Chicago, Illinois, 60611, United States
Local Institution - 0096
NOT_YET_RECRUITING

Esplugues de Llobregat, Barcelona [Barcelona], 08950, Spain
Local Institution - 0102
WITHDRAWN

Porto, 4200-319, Portugal
Local Institution - 0114
NOT_YET_RECRUITING

Loma Linda, California, 92354, United States
Local Institution - 0131
NOT_YET_RECRUITING

New Brunswick, New Jersey, 08901, United States
Local Institution - 0132
WITHDRAWN

Teaneck, New Jersey, 07666, United States
Local Institution - 0133
NOT_YET_RECRUITING

El Paso, Texas, 79912, United States
Local Institution - 0134
NOT_YET_RECRUITING

Caguas, 00725, Puerto Rico
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
National Taiwan University Hospital
RECRUITING

Taipei, 10002, Taiwan
Neurological Center Of Latium
RECRUITING

Rome, Roma, 00178, Italy
Ondokuz Mayıs Universitesi
RECRUITING

Samsun, 55270, Turkey (Türkiye)
Ospedale San Raffaele
RECRUITING

Milan, Lombardy, 20132, Italy
Prof. Dr. Alexandru Obregia Psychiatry Hospital
RECRUITING

Bucharest, Bucharest, 041914, Romania
Royal Children's Hospital
RECRUITING

Melbourne, Victoria, 3052, Australia
Spitalul Clinic de Copii Doctor Victor Gomoiu
RECRUITING

Bucharest, Bucharest, 022102, Romania
Unidade Local de Saúde de Coimbra, E.P.E.
RECRUITING

Coimbra, 3000-602, Portugal
University of California Davis Health
RECRUITING

Sacramento, California, 95817, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Louisville, Norton Children's Research Institute
RECRUITING

Louisville, Kentucky, 40202, United States
University of Naples Federico II
RECRUITING

Naples, Campania, 80131, Italy
University of South Florida
RECRUITING

Tampa, Florida, 33612, United States
Uniwersytecki Szpital Kliniczny w Poznaniu
RECRUITING

Poznan, Greater Poland Voivodeship, 60-355, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.